Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-NivoHF10
NCT03259425Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Jan 2018
- Primary completion
- Sep 2018
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canerpaturev in melanoma, sponsored by University of Utah. Primary endpoint: Pathological Response at 12 weeks. Started Jan 2018; status: terminated.
02
Drugs
canerpaturev
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03259425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259425.